Navigation Links
BioMarin Re-Acquires Rights to Kuvan in Canada From Merck Serono
Date:12/18/2007

product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(TM) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) for the treatment of PKU. For additional information, please visit http://www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking Statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the use of its product Kuvan; the potential market for Kuvan; expectations regarding filings with regulatory agencies; and the development of 6R-BH4 for other indications. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: the practices of physicians in using Kuvan; the actual response in patients using Kuvan in commercial distribution; the content and timing of decisions by the U.S. Food and Drug Administration, the European Medicines Agency and other regulatory authorities concerning Kuvan; results and timing of current and planned clinical trials of 6R-BH4 for other indications; and those factors detailed in BioM
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. BioMarin to Present at the Bear Stearns 20th Annual Healthcare Conference
2. BioMarin Provides Grant to NORD to Expand PKU Patient Support Services
3. Civil Rights and Medical Leaders Call for Social Justice in Health Care
4. Flynn Pharma Acquires Rights From Pacira Pharmaceuticals to DepoDur(R), the Only Extended-Release Epidural Opioid for Post-Operative Pain, in Europe
5. New Report Says Health Courts Bureaucracies Offer Big Financial Burdens and Loss of Patient Rights
6. Federal Trade Commission Attempts To Suppress Best-Selling Authors First Amendment Rights
7. Genaera Corporation Announces Licensing of Exclusive Rights to Pexiganan, a Novel Anti-Infective Drug Candidate, by Macrochem Corporation
8. Human rights violations widespread in eastern Burma
9. NOVT Corporations Board of Directors Terminates Shareholder Rights Plan
10. Laser Energetics Delivers BrightStar(TM) Alexandrite Laser to Fortune 50 Defense Company
11. Optherion Licenses Worldwide Rights to Develop Age-Related Macular Degeneration Diagnostics Based on Chromosome 10 Genetic Variations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... CA (PRWEB) July 31, 2014 Staying happy ... be tricky at best. Men and women get sucked into ... wives, life partners, and taxi services to kids. , ... offers her "3 Fast + Fun Ways to Reignite the ... download . , “This is a much better path ...
(Date:7/31/2014)... your life but no matter how hard you hit, ... can be said of highly treatment-resistant cancers, such as ... some cancer cells repair themselves, survive and thrive. Head ... in the world, but the late detection and treatment ... Now, University of Michigan researchers have found that a ...
(Date:7/31/2014)... July 31, 2014 Updox, the ... care, announces the release of a “Twelve Questions to Ask ... hospitals that are evaluating Health Information Service Providers (HISPs) for ... that utilize MEDITECH and Epic electronic health records (EHRs) need ... transitions of care using the Direct protocol. , ...
(Date:7/31/2014)... National non-profit World T.E.A.M. Sports’ annual ... Range September 12-14, following two years in the high ... of disabled and able-bodied athletes competing together in an ... challenging by experienced adventure athletes. , Hosted at the ... the Colorado River in the rugged Gore Mountains northwest ...
(Date:7/31/2014)... NY (PRWEB) July 31, 2014 Dolce ... , will be available in New York's favorite specialty ... August. BRC is known for their commitment to Fair ... Press. , Chocolatto® is the new sensation from Italy ... chocolate ! A delicious highly popular Italian dessert descended ...
Breaking Medicine News(10 mins):Health News:Couples in Trouble Relationship Expert, Dr. Jackie Black, Offers a Gift Guide to Reignite the Spark So Lovers Can Kiss-And-Make-Up 2Health News:Couples in Trouble Relationship Expert, Dr. Jackie Black, Offers a Gift Guide to Reignite the Spark So Lovers Can Kiss-And-Make-Up 3Health News:Updox Introduces Resources to Help Hospitals Choose the Right HISP for Direct Messaging 2Health News:Updox Introduces Resources to Help Hospitals Choose the Right HISP for Direct Messaging 3Health News:Updox Introduces Resources to Help Hospitals Choose the Right HISP for Direct Messaging 4Health News:World T.E.A.M. Sports’ Adventure Team Challenge Returns to Colorado’s High Country 2Health News:World T.E.A.M. Sports’ Adventure Team Challenge Returns to Colorado’s High Country 3Health News:Dolce Vite Chocolatto® - World's Best Thick Dark Italian Hot Chocolate Now Available at NYC's Favorite Cafe Brooklyn Roasting Company 2
... CITY, Calif., Sept. 30 Genomic Health, Inc. ... Health,s Chief Operating Officer and Chief Financial Officer, will present ... City, on Tuesday, October 6 at 9:30 a.m. ET. ... the presentation, visit the Investor Relations section of Genomic Health,s ...
... October is National Breast Cancer Awareness Month and Topcor is ... , Available October 5th, "Clipa for a Cure" is a ... Topcor will donate 10% of the retail price of every ... American Cancer Society, breast cancer is the second leading cause ...
... ... that they now help physicians find jobs on Twitter by using the popular social ... providers. , ... CO (PRWEB) September 29, 2009 -- Onyx M.D., a Denver, Colorado-based physician recruiting company, ...
... ... live. Everyone, including doctors, administrators, nurses, et al, are encouraged to go online to ... ... first multi-disciplinary, online healthcare community. It is designed for everyone in the medical field ...
... The American Federation of Government Employees expresses grave concern at the ... would be rising by an average of 8.8% in 2010. ... for 60% of the enrollees in FEHBP, those covered by Blue ... by 15% for self coverage and 12% for family coverage. ...
... PARSIPPANY, N.J., Sept. 30 Thousands of bacteria lurk ... hygiene routines to help protect themselves from serious illness, ... College Center for Hygiene and Health in Home and ... products.(1) Despite growing concerns about influenza A (H1N1) on ...
Cached Medicine News:Health News:'Clipa for a Cure': New Pink Instant Handbag Hanger Benefits Breast Cancer Research 2Health News:Onyx M.D. Now Tweet Jobs for Physician Job Opportunities by Specialty 2Health News:Onyx M.D. Now Tweet Jobs for Physician Job Opportunities by Specialty 3Health News:Online Healthcare Community, TogetherMD, is Live 2Health News:Study Shows College Students Are Not Following CDC Recommendations to Help Protect Themselves from H1N1 and Other Threatening Germs 2Health News:Study Shows College Students Are Not Following CDC Recommendations to Help Protect Themselves from H1N1 and Other Threatening Germs 3Health News:Study Shows College Students Are Not Following CDC Recommendations to Help Protect Themselves from H1N1 and Other Threatening Germs 4Health News:Study Shows College Students Are Not Following CDC Recommendations to Help Protect Themselves from H1N1 and Other Threatening Germs 5
(Date:7/30/2014)... , July 30, 2014  Decision Resources Group ... preclinical animal research imaging system market will ... imaging, such as combining computed tomography and magnetic ... This demand stems from the need for higher-quality ... scientific journals, which will spur preclinical imaging system ...
(Date:7/30/2014)... N.J. , July 30, 2014 Stryker brand ambassadors ... this week at the 3M Championship Champions Tour event near ... Cities, in Blaine . Stryker is the official ... Starting Friday, August 1 st through Sunday, ... Stryker Mobility Zone; an on-site joint health destination located in the ...
(Date:7/30/2014)... and PARIS , July 30, 2014 ... and Sanofi (EURONEXT: SAN and NYSE: SNY ... trials of alirocumab in people with hypercholesterolemia met their ... baseline in low-density lipoprotein cholesterol (LDL-C) at 24 weeks ... investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type ...
Breaking Medicine Technology:Growing Popularity of Multimodality Imaging Will Drive the Preclinical Animal Research Imaging System Market 2Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 2Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 3Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 4Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: